Patient Reported Outcome (PRO) assessment in epilepsy: a review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements

Ítems similars

• Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
  per: Amira Osman, et al.
  Publicat: (2018-04-01)
• Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
  per: Osman, Amira, et al.
  Publicat: (2018)
• Food and microbiota in the FDA regulatory framework
  per: Green, Jonathan M., et al.
  Publicat: (2017)
• Interpreting change from patient reported outcome (PRO) endpoints: patient global ratings of concept versus patient global ratings of change, a case study among osteoporosis patients
  per: Nixon, Annabel, et al.
  Publicat: (2016)
• Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies
  per: Nguyen, Diane, et al.
  Publicat: (2013)